Altratech is a pioneering brand in the field of next-generation molecular detection. With a team of twenty scientists and engineers, including nine PhDs, Altratech has spent seven years researching and developing a Bioorthogonal alternative to PCR. Their groundbreaking technology enables the monitoring of viral contagious diseases right at the point of care, whether it be in a clinical setting, at home, or anywhere else.

The Altratech product and assay can rapidly detect and quantify molecular targets from any sample with minimal preparation. Utilizing nanotechnology, semiconductor technology, and novel PNA chemistry, their assay named Molecular Detection by Proxy is a bead-based technology coupled with ultra-sensitive capacitance detection. Altratech's unique value proposition lies in their synthetic and robust PNA molecules, which require no cold-chain shipping or refrigeration and target the RNA virus directly in-situ, eliminating the need for sample-prep or extraction.

Additionally, Altratech offers the 'Altra-PNA-designer' software tool, which automates the design of PNA probes, making them accessible to researchers, scientists, clinicians, and industry professionals. With their focus on decentralization and connected healthcare, Altratech is revolutionizing the way we manage contagious viral diseases